CRISPR Therapeutics AG vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
5.2
Bearish
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
CRSP
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ low return on equity (-30%).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $83.35 (+61.4%)
23 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
CRSP
JNJ
—
Trailing P/E
26.3×
-12.9×
Forward P/E
17.9×
0.0%
Profit Margin
21.8%
0.0%
Gross Margin
68.0%
-30.2%
ROE
26.4%
-97.6%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
1.79
Beta
0.33
—
Price / Book
—
$5.0B
Market Cap
$546.9B
$33 – $78
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →